Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA) was the recipient of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 1,230,000 shares, a decrease of 63.1% from the July 31st total of 3,330,000 shares. Approximately 3.0% of the shares of the stock are sold short. Based on an average trading volume of 198,100 shares, the days-to-cover ratio is presently 6.2 days.

Hedge Funds Weigh In On Aura Biosciences

A number of hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. bought a new stake in Aura Biosciences in the second quarter valued at approximately $119,000. Trexquant Investment LP boosted its stake in shares of Aura Biosciences by 64.5% in the 4th quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock valued at $154,000 after purchasing an additional 6,809 shares during the last quarter. American International Group Inc. raised its stake in Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after buying an additional 3,782 shares during the last quarter. Virtu Financial LLC acquired a new stake in Aura Biosciences during the 1st quarter worth about $144,000. Finally, TBH Global Asset Management LLC raised its position in shares of Aura Biosciences by 82.3% in the 4th quarter. TBH Global Asset Management LLC now owns 60,322 shares of the company’s stock worth $534,000 after acquiring an additional 27,225 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Stock Down 1.5 %

NASDAQ AURA opened at $7.63 on Wednesday. The stock has a fifty day simple moving average of $8.21 and a 200 day simple moving average of $7.90. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.35. The company has a market capitalization of $378.01 million, a price-to-earnings ratio of -4.10 and a beta of 0.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright initiated coverage on shares of Aura Biosciences in a research report on Thursday, July 25th. They issued a “buy” rating and a $21.00 target price on the stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.